26 April 2017
SpeeDx and Thermo Fisher Scientific Strategic Partnership
SpeeDx and Thermo Fisher Scientific Announce Strategic Partnership for FDA Clearance of Molecular Diagnostic. ResistancePlus™ MG Test would bring disease and...
6 April 2017
Prospective Evaluation Study for ResistancePlus® MG
A prospective evaluation study published in the Journal of Clinical Microbiology evaluated our ResistancePlus® MG assay against 1089 symptomatic and asymptomatic...
17 February 2017
Nature Reviews Urology | Growing threat of macrolide resistant M. genitalium infections.
The authors of the review, Antimicrobial-resistant sexually transmitted infections: gonorrhoea and Mycoplasma genitalium, published in Nature Review Urology recommended that...
13 February 2017
The Age | Researchers raise concerns over sexually transmitted superbug
This drug-resistant sexually transmitted infection is behaving like a superbug and researchers estimate as many as 400,000 Australians may be...
2 February 2017
Evaluation of SpeeDx PlexPrime® and PlexZyme® technology published in PLOS One
SpeeDx Pty. Ltd. announced the publication of a novel technology, ‘Superior Multiplexing Capacity of PlexPrimers Enables Sensitive and Specific Detection...
17 January 2017
SpeeDx Receives TGA Approval For ResistancePlus MG
Mycoplasma genitalium (MG) is one of the fastest growing STIs in the world and has been reported to have a...
